Comparative Pharmacology
Head-to-head clinical analysis: BETIMOL versus DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETIMOL versus DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE.
BETIMOL vs DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonselective beta-adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production.
Dorzolamide is a carbonic anhydrase inhibitor that reduces aqueous humor secretion by inhibiting carbonic anhydrase in the ciliary processes. Timolol is a non-selective beta-adrenergic receptor antagonist that reduces aqueous humor production by blocking beta-2 adrenergic receptors in the ciliary epithelium.
1 drop of 0.25% or 0.5% solution in the affected eye(s) twice daily. If inadequate response, increase to 0.5% solution twice daily.
One drop of the fixed combination (dorzolamide 22.26 mg/mL, timolol 6.83 mg/mL) in the affected eye(s) every 12 hours.
None Documented
None Documented
2.5 to 5 hours (average 4 hours) in patients with normal renal function; may be prolonged in renal impairment (up to 8-10 hours).
Dorzolamide: ~4 months but accumulates in RBCs; terminal half-life ~4-5 months due to binding to carbonic anhydrase. Timolol: ~4-6 hours.
Primarily renal (unchanged drug and metabolites). Approximately 60-80% of a dose is excreted renally as unchanged timolol, with the remainder as inactive metabolites. Biliary/fecal excretion accounts for less than 20%.
Dorzolamide: primarily renal (approx. 80% unchanged), with minor biliary/fecal elimination. Timolol: renal (15-20% unchanged) and extensive hepatic metabolism with fecal excretion.
Category C
Category A/B
Beta-Blocker
Beta-Blocker